Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Joël Guigay is Professor of Medicine, Past Director of Cancer Center Antoine-Lacassagne in Nice, France, and Past President of the Head & Neck-Unicancer group. Prior to this, he was Head Physician in the Department of Head & Neck and Thoracic Medical Oncology at Gustave Roussy in Villejuif, France. Professor Guigay received his Medical Degree from Lyon University of Medicine, France, in 1984 and subsequently undertook extensive postgraduate training in Pneumology, Cancerology, Oncogenesis, and Thoracic Endoscopy. In 2001, he was appointed Professor of Medicine at the Hôpital d’Instruction des Armées Val-de-Grâce in Paris, France.
He currently serves as Head of partnerships and clinical development - Early assets for the Groupe Oncologie Radiothérapie Tête et Cou (GORTEC), and as deputy director of the Hospital University Federative OncoAge. In addition, he is an active member of many national and international societies, including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO) as a Faculty member for Head and Neck cancers and as a member of the OncologyPro WG, as Co-Chair of the scientific committee of the Head and Neck Cancer International Group (HNCIG).
His main fields of interest are head and neck and lung oncology with a focus on rare tumors, salivary gland tumors, nasopharyngeal cancers and neuroendocrine tumors. His areas of research include clinical studies with new drugs and translational research with a focus on immunotherapy. Professor Guigay coordinates several clinical trials including phase I to large randomized trials in recurrent or metastatic HNSCC such as TPExtreme trial. He currently leads also a large research program for elderly head and neck cancer patients (ELAN study).
Arif Hussain, MD, is Professor of Medicine with Tenure in the Department of Medicine, School of Medicine, at the University of Maryland in Baltimore, USA, where he is also Professor of Biochemistry in the Department of Biological Chemistry and Professor of Pathology in the Department of Pathology. He serves as Co-Leader of the Hormone Related Cancers Program at the University of Maryland Greenebaum Comprehensive Cancer Center. Dr Hussain's clinical interest is in genitourinary cancers, and he serves as Principal Investigator on several clinical trials that focus on therapies for high risk, recurrent and metastatic prostate cancer, as well as renal cell cancer. In addition, he has a research laboratory with a translational focus, studying drug resistance and adaptive intracellular signaling pathways in treatment-sensitive and treatment-resistant prostate cancer.